

AMENDMENTS TO THE CLAIMS

1. (Withdrawn) A combination product for the treatment of cancer in a mammal, said combination product comprising: an antisense oligonucleotide of between 7 and 100 nucleotides in length comprising at least 7 consecutive nucleotides complementary to a mammalian ribonucleotide reductase R2 subunit mRNA and one or more immunotherapeutic agents.
2. (Withdrawn) The combination product according to claim 1, wherein said mammalian ribonucleotide reductase R2 subunit mRNA is a human ribonucleotide reductase R2 subunit mRNA.
3. (Withdrawn) The combination product according to claim 2, wherein said human ribonucleotide reductase R2 subunit mRNA has a sequence as set forth in SEQ ID NO:105.
4. (Withdrawn) The combination product according to claim 2, wherein said antisense oligonucleotide comprises at least 7 consecutive nucleotides of the sequence as set forth in any one of SEQ ID NOs:1 and 4-104.
5. (Withdrawn) The combination product according to according to claim 2, wherein said antisense oligonucleotide comprises at least 7 consecutive nucleotides of the sequence as set forth in SEQ ID NO:1.
6. (Withdrawn) The combination product according to claim 1, wherein said antisense oligonucleotide comprises one or more phosphorothioate internucleotide linkages.
7. (Withdrawn) The combination product according to claim 1, wherein said cancer is an advanced cancer.

8. (Withdrawn) The combination product according to claim 1, wherein said cancer is a metastatic cancer.
9. (Withdrawn) The combination product according to claim 1, wherein said treatment is a first-line systemic therapy.
10. (Withdrawn) The combination product according to claim 1, wherein said one or more immunotherapeutic agents are non-specific immunotherapeutic agents.
11. (Withdrawn) The combination product according to claim 1, wherein said one or more immunotherapeutic agents are specific immunotherapeutic agents.
12. (Withdrawn) The combination product according to claim 1, wherein said one or more immunotherapeutic agents are a cytokine, a non-cytokine adjuvant, a monoclonal antibody or a cancer vaccine.
13. (Withdrawn) The combination product according to claim 1, wherein said one or more immunotherapeutic agents are a cytokine or a non-cytokine adjuvant.
14. (Withdrawn) The combination product according to claim 1, wherein said one or more immunotherapeutic agents are one or more cytokines.
15. (Withdrawn) The combination product according to claim 1, wherein said combination product further comprises one or more chemotherapeutic agents.
16. (Withdrawn) The combination product according to claim 1, wherein said cancer is a solid cancer.

17. (Withdrawn) The combination product according to claim 1, wherein said mammal is a human.

18. (Currently amended) A method of treating cancer in a ~~mammal~~ human comprising administering to said ~~mammal~~ human:

(a) an antisense oligonucleotide of between 7 and ~~100~~ 50 nucleotides in length comprising at least 7 consecutive nucleotides of the sequence as set forth in SEQ ID NO.:1 ~~complementary to a mammalian ribonucleotide reductase R2-subunit mRNA~~, and

(b) one or more cytokines selected from interferon alpha and interleukin-2 immunotherapeutic agents

wherein a combination of said antisense oligonucleotide and said one or more cytokines is more effective in treating cancer than either component of the combination when used alone.

19-22. (Cancelled)

23. (Previously presented) The method according to claim 18, wherein said antisense oligonucleotide comprises one or more phosphorothioate internucleotide linkages.

24. (Previously presented) The method according to claim 18, wherein said cancer is an advanced cancer.

25. (Previously presented) The method according to claim 18, wherein said cancer is a metastatic cancer.

26. (Previously presented) The method according to claim 18, wherein said method is a first-line systemic therapy.

27-31. (Cancelled).

32. (Currently amended) The method according to claim 18, wherein said method further comprises administering one or more chemotherapeutic agents to said ~~mammal~~human.

33. (Previously presented) The method according to claim 18, wherein said cancer is a solid cancer.

34-51. (Cancelled)

52. (Withdrawn) A pharmaceutical kit comprising a combination product for the treatment of cancer, said combination product comprising:

- (a) an antisense oligonucleotide of between 7 and 100 nucleotides in length comprising at least 7 consecutive nucleotides complementary to a mammalian ribonucleotide reductase R2 subunit mRNA, and
- (b) one or more immunotherapeutic agents.

53. (Withdrawn) A combination product for the treatment of renal cancer in a subject, said combination product comprising: an antisense oligonucleotide of between 7 and 100 nucleotides in length comprising at least 7 consecutive nucleotides complementary to SEQ ID NO:1 and one or more cytokines.

54. (Withdrawn) The combination product according to claim 53, wherein said one or more cytokines are interferon alpha or interleukin-2.

55. (Withdrawn) The combination product according to claim 53, wherein said treatment is a first-line systemic therapy.

56. (New) The method according to claim 18, wherein said antisense oligonucleotide is between about 10 and 50 nucleotides in length.

57. (New) The method according to claim 18, wherein said antisense oligonucleotide is between about 10 and 35 nucleotides in length.

58. (New) The method according to claim 18, wherein said antisense oligonucleotide is between about 12 and 35 nucleotides in length.

59. (New) The method according to claim 18, wherein said antisense oligonucleotide is between about 12 and 25 nucleotides in length.

60. (New) The method according to claim 18, wherein said antisense oligonucleotide comprises the sequence as set forth in SEQ ID NO:1.

61. (New) The method according to claim 18, wherein said antisense oligonucleotide consists of the sequence as set forth in SEQ ID NO:1.

62. (New) The method according to claim 18, wherein said antisense oligonucleotide is administered parenterally.

63. (New) The method according to claim 18, wherein said antisense oligonucleotide is administered intravenously.

- 64.(New) The method according to claim 18, wherein said one or more cytokines is interferon alpha.
- 65.(New) The method according to claim 18, wherein said one or more cytokines is interleukin-2.
- 66.(New) The method according to claim 18, wherein said one or more cytokines are administered parenterally.
- 67.(New) The method according to any one of claims 18, wherein said one or more cytokines are administered intratumourally.
- 68.(New) The method according to claim 18, wherein said cancer is a genitourinary tract cancer.
- 69.(New) The method according to claim 18, wherein said cancer is renal cancer.
- 70.(New) The method according to claim 18, wherein said cancer is renal cell carcinoma.
- 71.(New) The method according to claim 18, wherein the combination of said antisense oligonucleotide and said one or more cytokines produces an at least additive effect on one or more of tumour shrinkage, time to progression or survival.